ONT.L | Ticker Profile - Titan Protect

ONT.L

Oxford Nanopore Technologies plc

Healthcare · Biotechnology · LSE

$130.40

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.3B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-18.11

Based on estimated future earnings — lower means cheaper

Rev Growth

+19.4%

Year-over-year revenue change

Profit Margin

-64.8%

How much profit the company keeps from each dollar of revenue

ROE

-27.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$195.00

+50% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 12 analysts covering this stock

About Oxford Nanopore Technologies plc

Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA. The company offers MinION Mk 1D, a portable device for DNA and RNA sequencing; and GridION and GridION Q, a compact bench top device that delivers a version of hardware, software, and chemistry. It also provides PromethION products, such as PromethION 2, PromethION 24, and PromethION 48. The company has a collaboration with Cepheid to develop and commercialize automated infectious disease sequencing solutions. It operates in the region of Americas, Europe, the Middle East, Africa, India, and the Asia Pacific. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies plc in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is headquartered in Oxford, the United Kingdom.

https://nanoporetech.com

Country: United Kingdom Employees: 1,316 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.549

Good returns relative to risk taken

Kelly Fraction

0.0267

Modest edge detected — smaller position warranted

Calmar Ratio

0.312

Drawdown risk outweighs the returns — higher risk profile

Annual Return

16.3%

Historical annualised return based on price data

Max Drawdown

-52.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.87

Less volatile than the market — more defensive

52W High

$224.80

42% below the year high

52W Low

$104.00

25% above the year low

Avg Volume

1,639,839

Average daily shares traded — higher means easier to buy and sell

Short Ratio

N/A

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.15

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

8.96

Heavy leverage — higher financial risk if revenues decline

Current Ratio

3.56

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

2.73

Like current ratio but excludes inventory — stricter test

Gross Margin

60.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-48.7%

Profit from core operations before interest and tax

Free Cash Flow

$-35,650,000

Negative — the business is spending more than it generates

Revenue (TTM)

$224M

Total revenue over the last 12 months

Net Income

$-145,200,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$240.00

Target Median

$195.00

Target Low

$140.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go